Abstract
BACKGROUND: Treatment of non-clear cell renal cell carcinoma (RCC) remains controversial despite several recent prospective studies of targeted therapies (TT). Often Vascular Endothelial growth Factor (VEGF) and Mammalian Target of Rapamycin (mTOR) inhibitors are used, extrapolating the data from use of these agents in clear cell RCC.
METHODS: We performed a retrospective data analysis within the Renal Cross Channel Group to determine metastatic chromophobe RCC (mChRCC) outcomes in the TT era. The end-points were overall response, overall survival (OS) and time to treatment failure (TTF). The two latter were estimated using the Kaplan-Meier method.
RESULTS: 91 mChRCC patients from 26 centres were included. Median follow-up from the date of first metastasis was 6.1 years (range: 0-13.9). Median OS was 37.9 months (95% confidence interval [CI]: 21.4-46.8) from the diagnosis of metastatic disease. Among the 61 patients who received TT, 50 (82%) were treated with anti-angiogenic (AA) and 11 with mTOR inhibitors. Median TTF and OS in patients receiving a first line of AA was 8.7 months (95% CI: 5.2-10.9) and 22.9 months (95% CI: 17.8-49.2) versus 1.9 months (95% CI: 1.0-6.0) and 3.2 months (95% CI: 2.3-not evaluable) with mTOR inhibitors, respectively. A stratified log-rank test was used to compare AA and mTOR inhibitors TT, while controlling the effect of the International Metastatic RCC Database Consortium risk group and no significant difference between AA and mTOR inhibitors was observed for TTF (p = 0.26) or for OS (p = 0.55).
CONCLUSION: We report the largest retrospective cohort of patients with mChRCC treated with TT and no significant difference between AA and mTOR inhibitors was observed for TTF and OS.
| Original language | English |
|---|---|
| Pages (from-to) | 55-62 |
| Number of pages | 8 |
| Journal | European Journal of Cancer |
| Volume | 80 |
| DOIs | |
| Publication status | Published - Jul 2017 |
Fingerprint
Keywords
- Adult
- Aged
- Angiogenesis Inhibitors
- Antineoplastic Agents
- Carcinoma, Renal Cell
- Enzyme Inhibitors
- Female
- Humans
- Kaplan-Meier Estimate
- Kidney Neoplasms
- Male
- Middle Aged
- Molecular Targeted Therapy
- Retrospective Studies
- Survival Analysis
- TOR Serine-Threonine Kinases
- Time Factors
- Treatment Failure
- Journal Article
- Multicenter Study
Cite this
Metastatic chromophobe renal cell carcinoma treated with targeted therapies : A Renal Cross Channel Group study. / Colomba, Emeline; Le Teuff, Gwénaël; Eisen, Tim; Stewart, Grant D; Fife, Kate; Larkin, James; Biondo, Andrea; Pickering, Lisa; Srinivasan, Anandagopal; Boyle, Helen; Derosa, Lisa; Sternberg, Cora N; Recine, Federica; Ralph, Christy; Saldana, Carolina; Barthélémy, Philippe; Bernhard, Jean Christophe; Gurney, Howard; Verhoest, Gregory; Vauleon, Elodie; Bigot, Pierre; Berger, Julien; Pfister, Christian; Gravis, Gwenaelle; Rodier, Jean-Michel; Culine, Stéphane; Caty, Armelle; Rolland, Frederic; Priou, Franck; Escudier, Bernard; Albiges, Laurence.
In: European Journal of Cancer, Vol. 80, 07.2017, p. 55-62.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Metastatic chromophobe renal cell carcinoma treated with targeted therapies
T2 - A Renal Cross Channel Group study
AU - Colomba, Emeline
AU - Le Teuff, Gwénaël
AU - Eisen, Tim
AU - Stewart, Grant D
AU - Fife, Kate
AU - Larkin, James
AU - Biondo, Andrea
AU - Pickering, Lisa
AU - Srinivasan, Anandagopal
AU - Boyle, Helen
AU - Derosa, Lisa
AU - Sternberg, Cora N
AU - Recine, Federica
AU - Ralph, Christy
AU - Saldana, Carolina
AU - Barthélémy, Philippe
AU - Bernhard, Jean Christophe
AU - Gurney, Howard
AU - Verhoest, Gregory
AU - Vauleon, Elodie
AU - Bigot, Pierre
AU - Berger, Julien
AU - Pfister, Christian
AU - Gravis, Gwenaelle
AU - Rodier, Jean-Michel
AU - Culine, Stéphane
AU - Caty, Armelle
AU - Rolland, Frederic
AU - Priou, Franck
AU - Escudier, Bernard
AU - Albiges, Laurence
N1 - Copyright © 2017. Published by Elsevier Ltd.
PY - 2017/7
Y1 - 2017/7
N2 - BACKGROUND: Treatment of non-clear cell renal cell carcinoma (RCC) remains controversial despite several recent prospective studies of targeted therapies (TT). Often Vascular Endothelial growth Factor (VEGF) and Mammalian Target of Rapamycin (mTOR) inhibitors are used, extrapolating the data from use of these agents in clear cell RCC.METHODS: We performed a retrospective data analysis within the Renal Cross Channel Group to determine metastatic chromophobe RCC (mChRCC) outcomes in the TT era. The end-points were overall response, overall survival (OS) and time to treatment failure (TTF). The two latter were estimated using the Kaplan-Meier method.RESULTS: 91 mChRCC patients from 26 centres were included. Median follow-up from the date of first metastasis was 6.1 years (range: 0-13.9). Median OS was 37.9 months (95% confidence interval [CI]: 21.4-46.8) from the diagnosis of metastatic disease. Among the 61 patients who received TT, 50 (82%) were treated with anti-angiogenic (AA) and 11 with mTOR inhibitors. Median TTF and OS in patients receiving a first line of AA was 8.7 months (95% CI: 5.2-10.9) and 22.9 months (95% CI: 17.8-49.2) versus 1.9 months (95% CI: 1.0-6.0) and 3.2 months (95% CI: 2.3-not evaluable) with mTOR inhibitors, respectively. A stratified log-rank test was used to compare AA and mTOR inhibitors TT, while controlling the effect of the International Metastatic RCC Database Consortium risk group and no significant difference between AA and mTOR inhibitors was observed for TTF (p = 0.26) or for OS (p = 0.55).CONCLUSION: We report the largest retrospective cohort of patients with mChRCC treated with TT and no significant difference between AA and mTOR inhibitors was observed for TTF and OS.
AB - BACKGROUND: Treatment of non-clear cell renal cell carcinoma (RCC) remains controversial despite several recent prospective studies of targeted therapies (TT). Often Vascular Endothelial growth Factor (VEGF) and Mammalian Target of Rapamycin (mTOR) inhibitors are used, extrapolating the data from use of these agents in clear cell RCC.METHODS: We performed a retrospective data analysis within the Renal Cross Channel Group to determine metastatic chromophobe RCC (mChRCC) outcomes in the TT era. The end-points were overall response, overall survival (OS) and time to treatment failure (TTF). The two latter were estimated using the Kaplan-Meier method.RESULTS: 91 mChRCC patients from 26 centres were included. Median follow-up from the date of first metastasis was 6.1 years (range: 0-13.9). Median OS was 37.9 months (95% confidence interval [CI]: 21.4-46.8) from the diagnosis of metastatic disease. Among the 61 patients who received TT, 50 (82%) were treated with anti-angiogenic (AA) and 11 with mTOR inhibitors. Median TTF and OS in patients receiving a first line of AA was 8.7 months (95% CI: 5.2-10.9) and 22.9 months (95% CI: 17.8-49.2) versus 1.9 months (95% CI: 1.0-6.0) and 3.2 months (95% CI: 2.3-not evaluable) with mTOR inhibitors, respectively. A stratified log-rank test was used to compare AA and mTOR inhibitors TT, while controlling the effect of the International Metastatic RCC Database Consortium risk group and no significant difference between AA and mTOR inhibitors was observed for TTF (p = 0.26) or for OS (p = 0.55).CONCLUSION: We report the largest retrospective cohort of patients with mChRCC treated with TT and no significant difference between AA and mTOR inhibitors was observed for TTF and OS.
KW - Adult
KW - Aged
KW - Angiogenesis Inhibitors
KW - Antineoplastic Agents
KW - Carcinoma, Renal Cell
KW - Enzyme Inhibitors
KW - Female
KW - Humans
KW - Kaplan-Meier Estimate
KW - Kidney Neoplasms
KW - Male
KW - Middle Aged
KW - Molecular Targeted Therapy
KW - Retrospective Studies
KW - Survival Analysis
KW - TOR Serine-Threonine Kinases
KW - Time Factors
KW - Treatment Failure
KW - Journal Article
KW - Multicenter Study
U2 - 10.1016/j.ejca.2017.03.011
DO - 10.1016/j.ejca.2017.03.011
M3 - Article
C2 - 28549248
VL - 80
SP - 55
EP - 62
JO - European Journal of Cancer
JF - European Journal of Cancer
SN - 0959-8049
ER -